- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, ...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.

today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones. “2024 was a landmark year for 4DMT, driven by groundbreaking clinical ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. National League N / S All competitions All competitions All competitions ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...

beat consensus estimates with its full-year payout, delivering 60% of 2024 profits to shareholders in the form of a $4.02 full year dividend. That saw returns fall 8% to US$6.5bn ($10.24bn) as ...

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Dr. Sándor ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...